Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Conclusions 177Lu-PSMA-617 radionuclide therapy is a safe and effective approach to the treatment of mCRPC patients.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research

Related Links:

No abstract available
Source: Nursing - Category: Nursing Tags: Department: INFOBYTES Source Type: research
Date: Thursday, 03 05, 2020; Speaker: Dr. Randy Jones, University of Virginia School of Nursing; Building: Building 10 (Clinical Center); Lipsett Amphitheater; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
For men in VA health system, blacks do not present with more advanced disease or have higher mortality
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Urology, Journal, Source Type: news
Ground zero workers had higher rates of cancer, especially prostate and thyroid cancers and leukemia.
Source: NYT Health - Category: Consumer Health News Authors: Tags: World Trade Center (Manhattan, NY) Cancer Prostate Cancer Thyroid Cancer Leukemia Mount Sinai Medical Center Source Type: news
Disparities in medical care may account for why African-American men with prostate cancer are almost twice as likely to die as white men with the disease.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Black People Prostate Cancer Race and Ethnicity Prostate Gland Source Type: news
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
MONDAY, Jan. 27, 2020 -- For men diagnosed with prostate cancer in the Veterans Affairs health system, African-Americans (AAs) do not present with more advanced disease or have worse outcomes compared with non-Hispanic whites (NHWs), according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Beyond simply being discontent about the high cost of health care in the nation, consumers remain in the dark over what that cost may be – even for a standard treatment for prostate cancer, according to a study out of UNC-Chapel Hill.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
(Wiley) Among men with prostate cancer who received care from the Veterans Affairs (VA) Health System, an equal-access health care system, African-American men did not have more advanced disease at the time of diagnosis or die earlier than white men, unlike trends seen in the greater US population of patients with prostate cancer. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Vanderbilt University Medical Center) A five-year follow-up study of more than 2,000 US men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hormonal Therapy | Hormones | Laboratory Medicine | Nuclear Medicine | Prostate Cancer | Radiography | Study | Taxotere | Toxicology